Provided by Tiger Trade Technology Pte. Ltd.

Connect Biopharma Holdings Ltd.

2.36
+0.08003.51%
Post-market: 2.33-0.0300-1.27%19:30 EDT
Volume:444.95K
Turnover:1.03M
Market Cap:148.59M
PE:-1.98
High:2.37
Open:2.30
Low:2.21
Close:2.28
52wk High:3.82
52wk Low:1.23
Shares:62.96M
Float Shares:21.07M
Volume Ratio:1.04
T/O Rate:2.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1933
EPS(LYR):-1.0000
ROE:-140.51%
ROA:-69.75%
PB:5.53
PE(LYR):-2.36

Loading ...

Connect Biopharma FY25 net loss widens to $55.5 million; cash, investments fall to $44 million

Reuters
·
Apr 01

Press Release: Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Dow Jones
·
Apr 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (SNY), Milestone Pharmaceuticals (MIST) and Connect Biopharma Holdings (CNTB)

TIPRANKS
·
Mar 31

Connect Biopharma Price Target Maintained With a $10.00/Share by BTIG

Dow Jones
·
Mar 31

Connect Biopharma Shares Decline on Private Placement

Dow Jones
·
Mar 31

BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar

Reuters
·
Mar 30

Analysts Conflicted on These Healthcare Names: Connect Biopharma Holdings (CNTB), Neumora Therapeutics, Inc. (NMRA) and Merck & Company (MRK)

TIPRANKS
·
Mar 30

Connect Biopharma Announces Positive Topline Data From Its Phase 1 Study Of Intravenous (Iv) Rademikibart In Patients With Asthma Or Copd

Reuters
·
Mar 30

BRIEF-Rademikibart Demonstrates Best-In-Class Potential In Phase 3 Atopic Dermatitis Study

Reuters
·
Mar 30

BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike

Reuters
·
Mar 30

Connect Biopharma Highlights Positive Rademikibart Respiratory Trial Results

TIPRANKS
·
Mar 30

BUZZ-Connect Biopharma rises as eczema drug shows lasting benefit in China study

Reuters
·
Mar 30

Connect Biopharma says rademikibart hits EASI-75 in 96.6% in Phase 3 AD trial

Reuters
·
Mar 30

Connect Biopharma says Phase 1 IV rademikibart trial shows rapid FEV1 improvement in asthma, COPD

Reuters
·
Mar 30

Press Release: Connect Biopharma Announces $20.2 Million Private Placement Financing

Dow Jones
·
Mar 30

Connect Biopharma Holdings Ltd - Rademikibart Achieves Rapid, Durable Efficacy in Phase 3 Atopic Dermatitis Study Through 52 Weeks

THOMSON REUTERS
·
Mar 30

Connect Biopharma Holdings Ltd - Rademikibart Well Tolerated With Safety Comparable to Placebo

THOMSON REUTERS
·
Mar 30

Connect Biopharma Holdings Ltd - Rademikibart Well-Tolerated With No Serious or Severe Adverse Events

THOMSON REUTERS
·
Mar 30

Connect Biopharma Holdings Ltd - Recruitment Ongoing for Phase 2 Seabreeze Stat Studies; Topline Data Expected Mid-2026

THOMSON REUTERS
·
Mar 30

Connect Biopharma Holdings Ltd - Rademikibart 300 Mg Iv Push Produces Rapid Fev1 Improvement ≥200 Ml in Asthma and Copd

THOMSON REUTERS
·
Mar 30